Research programme: pyrimidinedione analogues - ImQuest/Samjin

Drug Profile

Research programme: pyrimidinedione analogues - ImQuest/Samjin

Alternative Names: IQP-0528; IQP-0568; IQP-0589; IQP-1187; Second-generation pyrimidinediones - ImQuest/Samjin

Latest Information Update: 22 Jul 2014

Price : $50

At a glance

  • Originator Samjin Pharmaceutical Company
  • Developer ImQuest Life Sciences; University of Utah
  • Class Pyrimidinones; Small molecules
  • Mechanism of Action Hepatitis C virus replication inhibitors; RNA-directed DNA polymerase inhibitors; Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Hepatitis B; Hepatitis C; HIV infections

Most Recent Events

  • 16 Jul 2014 The US FDA approves IND application for IQP 0528 in HIV infections (prevention)
  • 11 Feb 2009 Antimicrobial and animal toxicology data from preclinical trials for HIV infections presented at the 16th Conference on Retroviruses and Opportunistic Infections (CROI-2009)
  • 29 Jul 2008 Preclinical trials in HIV infections prevention in USA (Topical, Gel)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top